Risk and characteristics of tuberculosis after anti-tumor necrosis factor therapy for inflammatory bowel disease: a hospital-based cohort study from Korea

• Published in: BMC gastroenterology Vol. 21; no. 1; pp. 1 - 390
• Main Authors: Lee, Jae Yong, Oh, Kyunghwan, Hong, Hee Seung, Kim, Kyuwon, Hong, Seung Wook, Park, Jin Hwa, Hwang, Sung Wook, Yang, Dong-Hoon, Ye, Byong Duk, Byeon, Jeong-Sik, Myung, Seung-Jae, Yang, Suk-Kyun, Lee, Ho-Su, Jo, Kyung-Wook, Park, Sang Hyoung
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 20.10.2021; BioMed Central; BMC
• Subjects: Age; Cohort analysis; Complications and side effects; Crohn's disease; Disease prevention; Drug therapy; Gastroenterology; Hospital patients; Infections; Inflammatory bowel disease; Inflammatory bowel diseases; Intestine; Latent tuberculosis; Necrosis; Patients; Risk factors; Statistics; Steroids; Tuberculosis; Tumor necrosis factor; Tumor necrosis factor inhibitor; Tumor necrosis factor inhibitors; Tumor necrosis factor-TNF; Ulcerative colitis; South Korea
• ISSN: 1471-230X; 1471-230X
• DOI: 10.1186/s12876-021-01973-5

Abstract Background Anti-tumor necrosis factor (TNF) treatment for inflammatory bowel disease (IBD) increases the risk of tuberculosis (TB) infection. In the present study, we analyzed the clinical characteristics and risks of TB in Korean patients with IBD who received anti-TNF treatment. Methods The study included patients with IBD who were treated using anti-TNF agents between January 2001 and June 2018 at the Asan Medical Center. Overall, 1434 patients with ulcerative colitis or Crohn’s disease were enrolled. We calculated the incidence of active TB infection after anti-TNF treatment and compared the clinical characteristics of the TB group with those of the non-TB group. Results Twenty-one patients (1.46%) developed active TB infection, and the incidence rate of active TB was 366.73 per 100,000 person-years. In total, 198 patients (14.9%) were positive for latent tuberculosis infection (LTBI), of whom only eight (4%) did not complete LTBI treatment. The age at which the anti-TNF therapy was started was significantly higher in the TB group than in the non-TB group (HR 1.041, 95% CI 1.014–1.069, p  = 0.002), and as age increased, so did the incidence rate of active TB infection (linearity p  < 0.001). There was no significant difference in the incidence rate of LTBI between the TB and non-TB groups (HR 0.896, 95% CI 0.262–3.066, p  = 0.862). Conclusions In patients with IBD, the incidence rate of TB increased with age at anti-TNF therapy initiation. Active treatment of LTBI may lower the incidence of TB in patients with IBD who are to undergo anti-TNF therapy.